Jade Biosciences
JBIO
105 hedge funds and large institutions have $726M invested in Jade Biosciences in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 44 increasing their positions, 14 reducing their positions, and 6 closing their positions.
450% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 6
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
214% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 14
166% more capital invested
Capital invested by funds: $273M → $726M (+$453M)
35% more funds holding
Funds holding: 78 → 105 (+27)
1.45% less ownership
Funds ownership: 96.91% → 95.46% (-1.4%)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $1.76M
Top Buyers
Top Sellers
JBIO Hedge Fund Activity: Q4 2025 in Review
105 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q4 2025, worth a combined $726M — up 166% from $273M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new JBIO positions and 6 closed out — a net gain of 27 holders — while 44 added to existing stakes and 14 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $39.2M. The largest seller was Deep Track Capital, exiting entirely with an estimated $19.7M sold.
- 105 institutional investors held Jade Biosciences (JBIO) as of Q4 2025, up from 78 in Q3 2025.
- Funds reported $726M of Jade Biosciences stock for Q4 2025, up 166% quarter-over-quarter.
- 33 funds opened new Jade Biosciences positions in Q4 2025 and 6 closed out, a net change of +27 holders.
- The largest Jade Biosciences buyer in Q4 2025 was Bellevue Group, an estimated $39.2M added.
- The largest Jade Biosciences seller in Q4 2025 was Deep Track Capital, an estimated $19.7M sold.
Based on aggregated 13F filings for Q4 2025.